Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

NCT00558259 ·Status: COMPLETED ·Phase: PHASE3

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

NCT00818753 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330 ·Status: COMPLETED ·Phase: PHASE3

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

NCT02171624 ·Status: COMPLETED ·Phase: PHASE1

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971 ·Status: COMPLETED ·Phase: PHASE3

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

NCT01773174 ·Status: WITHDRAWN ·Phase: PHASE2

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

NCT03742336 ·Status: COMPLETED ·Phase: PHASE1

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

NCT03254134 ·Status: COMPLETED

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238 ·Status: COMPLETED ·Phase: PHASE3

RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

NCT00168805 ·Status: COMPLETED ·Phase: PHASE3

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

NCT01976507 ·Status: COMPLETED ·Phase: PHASE4

Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

NCT01810237 ·Status: WITHDRAWN ·Phase: NA

Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe

NCT02240654 ·Status: COMPLETED

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

NCT02149303 ·Status: COMPLETED

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150 ·Status: COMPLETED ·Phase: PHASE3

Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

NCT01704053 ·Status: COMPLETED

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

NCT02596555 ·Status: TERMINATED ·Phase: PHASE4

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics

NCT01210755 ·Status: COMPLETED ·Phase: PHASE4

Effect of Inhibitors of the Proton Pump on Intestinal Transporters

NCT02524210 ·Status: COMPLETED ·Phase: PHASE1

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

NCT00246025 ·Status: COMPLETED ·Phase: PHASE2

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

NCT02061748 ·Status: COMPLETED

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

NCT01436526 ·Status: COMPLETED ·Phase: PHASE1

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

NCT06387407 ·Status: NOT_YET_RECRUITING

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

NCT00168818 ·Status: COMPLETED ·Phase: PHASE3